Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Borderline Personality Disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Borderline Personality Disorder. Displaying page 1 of 1.
    EudraCT Number: 2020-000078-12 Sponsor Protocol Number: 1402-0012 Start Date*: 2020-10-15
    Sponsor Name:Boehringer Ingelheim
    Full Title: A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients ...
    Medical condition: borderline personality disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10006033 Borderline personality LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) PL (Ongoing) DE (Completed) BG (Completed) DK (Completed) CZ (Completed) BE (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-020956-69 Sponsor Protocol Number: OX02 Start Date*: 2011-02-23
    Sponsor Name:Universitätsklinikum Freiburg
    Full Title: Effekte von Oxytocin bei Patientinnen und Patienten mit Borderline-Persönlichkeitsstörung
    Medical condition: ICD-10 F60.3 Emotionally unstable personality disorder Two types may be distinguished: the impulsive type, characterized by emotional instability and lack of impulse control, and the borderline typ...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10006034 Borderline personality disorder PT
    17.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003469-20 Sponsor Protocol Number: CL07-ORY-2001 Start Date*: 2020-11-06
    Sponsor Name:Oryzon Genomics S.A.
    Full Title: A double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population (POR...
    Medical condition: Borderline Personality Disorder (BPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10006034 Borderline personality disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-002813-20 Sponsor Protocol Number: 331-201-00242 Start Date*: 2020-03-16
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder
    Medical condition: Borderline Personality Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10006034 Borderline personality disorder PT
    21.1 10037175 - Psychiatric disorders 10006033 Borderline personality LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002471-18 Sponsor Protocol Number: Start Date*: 2019-01-18
    Sponsor Name:Imperial College London
    Full Title: The clinical effectiveness and cost effectiveness of clozapine for inpatients with borderline personality disorder: randomised controlled trial
    Medical condition: Borderline Personality Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10006034 Borderline personality disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-001212-30 Sponsor Protocol Number: ECEP-BPD Start Date*: 2018-09-18
    Sponsor Name:Central Institute of Mental Health, represented by commercial and administrative Director
    Full Title: A trial to study effects of a single dose Citalopram on emotion processing in female patients with Borderline Personality Disorder and the associated modulation of fMRI BOLD signals
    Medical condition: Borderline Personality Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10006034 Borderline personality disorder PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000749-21 Sponsor Protocol Number: 4.20 Start Date*: 2016-03-14
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: Botulinumtoxin A for emotional stabilization in borderline personality disorder
    Medical condition: Borderline personality disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003670-22 Sponsor Protocol Number: IIBSP-OXI-2022-124 Start Date*: 2023-07-31
    Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau
    Full Title: Controlled and randomized clinical trial to evaluate the efficacy of the combination of oxytocin plus self-compassion training in patients with Borderline Personality Disorder
    Medical condition: Borderline personality disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002897-30 Sponsor Protocol Number: 331-201-00195 Start Date*: 2020-02-19
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc
    Full Title: A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder
    Medical condition: Borderline Personality Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10006034 Borderline personality disorder PT
    21.1 10037175 - Psychiatric disorders 10006033 Borderline personality LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-002140-88 Sponsor Protocol Number: CL04-ORY-2001 Start Date*: 2018-09-06
    Sponsor Name:Oryzon Genomics S.A.
    Full Title: An unicenter, open-label, 1-arm, 8-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in adult population with Alzheimer’s Disease (AD), Lewy Body Dementia (LBD)...
    Medical condition: Agression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10001488 Aggression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003136-23 Sponsor Protocol Number: CRO1990 Start Date*: 2012-11-27
    Sponsor Name:Imperial College London
    Full Title: Lamotrigine And Borderline Personality Disorder: Investigating Long-Term Effectiveness
    Medical condition: Borderline Personality Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10042033 Stevens-Johnson syndrome PT
    14.1 10029205 - Nervous system disorders 10019211 Headache PT
    15.0 100000004856 10028821 Nausea with vomiting LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10040913 Skin rash LLT
    14.1 10029205 - Nervous system disorders 10024264 Lethargy PT
    14.1 10029205 - Nervous system disorders 10013649 Drowsiness LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001490-15 Sponsor Protocol Number: RIS-BMN-3001 Start Date*: 2007-04-23
    Sponsor Name:Janssen-Cilag International N.V
    Full Title: A randomized, double-blind, placebo- and active-controlled, parallel-group study to evaluate the efficacy and safety of risperidone long-acting injectable for the prevention of mood episodes in the...
    Medical condition: Subjects with a diagnosos of bipolar I disorder who are currently experiencing a manic or mixed episode (YMRS>20 and CGI-S>/= 4 [moderate]) or who are between mood episodes (non-acute; YMRS<12 and ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10004939 Bipolar I disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002577-22 Sponsor Protocol Number: COMP003 Start Date*: Information not available in EudraCT
    Sponsor Name:COMPASS Pathfinder, Limited
    Full Title: The safety and efficacy of psilocybin as an adjunctive therapy in participants with treatment-resistant depression
    Medical condition: treatment resistant depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    21.1 100000004873 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022914-15 Sponsor Protocol Number: A3051123 Start Date*: 2012-03-01
    Sponsor Name:Pfizer, S.L.U.
    Full Title: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO -CONTROLLED, MULTICENTER STUDY EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF 12 WEEKS VARENICLINE TARTRATE 1MG BID AND BUPROPION HYD...
    Medical condition: Nicotine Addiction with the desire to quit smoking
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10053325 Smoking cessation therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) DK (Completed) FI (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2017-003288-36 Sponsor Protocol Number: COMP001 Start Date*: 2018-03-09
    Sponsor Name:COMPASS Pathways, Ltd
    Full Title: The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression (P-TRD)
    Medical condition: Treatment-Resistant Depression (P-TRD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    21.1 100000004873 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) PT (Completed) NL (Completed) IE (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:25:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA